PharmTech Drug Digest 11.20
News|Articles|January 9, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-02-01-2017
  • Volume 12
  • Issue 2

Catalent to Develop Softgels for Orphan Drug Candidate

Catalent announces a development agreement with JOT to evaluate softgel options for a resveratrol drug candidate.

Catalent Pharma Solutions has announced that the company will evaluate Jupiter Orphan Therapeutics, Inc.’s novel formulation of resveratrol, JOTROL, for delivery using Catalent’s R.P. Scherer softgel technology. Under the agreement announced Jan. 9, 2017, Catalent will assess different softgel delivery technologies for JOTROL to determine the optimum oral dosage form, before manufacturing doses for human pharmacokinetics studies and Phase II clinical studies.

JOTROL, which is being developed to remedy resveratrol’s poor bioavailability and dose limiting gastrointestinal side effects, is being studied in multiple pre-clinical and clinical trial programs for the treatment of rare diseases linked to single gene deficiencies, as reported in a press statement.

Catalent will assess both conventional softgel and Catalent’s proprietary OptiShell gelatin-free technology. Catalent reports that OptiShell allows for higher fill temperatures and pH, and can accommodate semi-solid and highly viscous formulations and a wider range of excipients designed to improve bioavailability and stability.

Catalent will conduct its work on JOTROL from its St. Petersburg, FL facility, which offers formulation development and manufacturing of prescription and over-the-counter softgels, and has an annual capacity of more than 18 billion capsules a year.

Source: Catalent Pharma Solutions

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.